
The study evaluated the efficacy of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) in type 2 diabetes (T2D) using derived time-in-range (dTIR). Data from the LixiLan trials showed iGlarLixi improved dTIR by 25.7%, compared to 15.8% for iGlar, 11.7% for Lixi, and 16.2% for GLP-1 RA. At the end of treatment, dTBR was 0.71% for iGlarLixi. These findings support iGlarLixi’s role in enhancing clinical outcomes in T2D with minimal hypoglycemia risk.
Like
Save
Share